Dr. Abdou on Race and Clinical Outcomes in Breast Cancer

Video

Yara Abdou, MD, discusses racial disparities in breast cancer outcomes in patients enrolled to the phase 3 RxPONDER trial.

Yara Abdou, MD, assistant professor, UNC School of Medicine, discusses racial disparities in breast cancer outcomes in patients enrolled to the phase 3 RxPONDER trial (NCT01272037).

In total, 4,048 patients were included in an analysis of clinicopathologic characteristics, survival outcomes, and race in the RxPONDER trial, Abdou says. Although this analysis found no significant differences in the number of positive lymph nodes or recurrence score distribution across all cohorts, tumor grade was found to be significantly different among the cohorts, Abdou notes.

Specifically, non-Hispanic Black patients had fewer low-grade tumors and more high-grade tumors vs non-Hispanic White patients, Abdou explains. Additionally, non-Hispanic Black patients had worse invasive disease-free survival and distant relapse-free survival rates vs non-Hispanic White patients, even when the data were adjusted for recurrence score, treatment arm, menopausal status, age, and grade, Abdou concludes.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine